Reform advances to facilitate access to naloxone as treatment for opioid overdose
In the Health Commission, the proposal of Senator Olga Sánchez Cordero and Senator Ricardo Monreal Ávila advanced to eliminate naloxone from the list of psychotropic substances, so that this drug can be bought without a prescription in pharmacies, as a treatment for reverse the effects of overdose from opioids such as fentanyl.
The senators highlighted that the scope of this reform represents a significant advance in the formulation of public policies, since it takes into account the effectiveness of decisions with a harm reduction approach, which represents an indisputable paradigm shift in responses to drug use.
It is a substance that has wide therapeutic uses, but due to its classification in the General Health Law, it is difficult to access for those who face an opioid overdose.
Therefore, the people who provide assistance at the time of the crisis resort to practices such as beating, placing ice or intravenously administering a concentrated solution of water with salt, methods that lack efficacy, particularly in those cases where there is the presence of fentanyl.
This, highlighted by the members of the Health Commission, chaired by Senator Lilia Margarita Valdez Martínez, implies a great risk to the lives of those who suffer from the overdose.
Naloxone, it is emphasized in the opinion, “is not a psychotropic substance because it does not produce alterations in the central nervous system”; In addition, it quickly counteracts the actions of opioids such as morphine, heroin, oxycodone, fentanyl and its derivatives.”
Naloxone is a life-saving medication that can reverse an overdose of opioids, including heroin, fentanyl, and prescription opioid medications. Naloxone is safe and easy to use, and is often given by nasal spray.
It can be administered with a nasal vaporizer or as an intramuscular, subcutaneous or intravenous injection, and it has no effect on those who do not have opioids in the body, is emphasized in the draft decree that reforms section IV of article 245 of the General Health Law.
The major issues for the further development of the pharmaceutical market will be discussed at the Mexican Pharmaceutical Forum that will be organized by the Global Pharmaceutical Leaders’ Club on the 29-30th November 2022 in Mexico City. Secure your delegate place ASAP! Registration is here: https://mexicanpharmaforum.com/registration/
Takeda appoints Hernán Porcile as its new General Manager in Mexico
October 24, 2022
Solid growth of the Medical Devices sector in Mexico
October 19, 2022
Sandoz Receives Certification for Transparent Practices
October 19, 2022